We are developing treatments which could revolutionize the care of patients with inner ear disorders
Our approach
Sensorion’s mission is to offer innovative therapeutic solutions providing long-term improvements to people living with, or at risk of, inner ear disorders. Sensorion’s portfolio of solutions to unmet medical and social needs in inner ear disorders rests on three pillars – Restore, Treat, Prevent.
We aim to restore hearing by treating genetic diseases previously regarded as untreatable.
We aim to treat hearing disorders through innovative small molecule therapeutic solutions.
We aim to prevent non-genetic hearing loss (e.g drug or surgery-related) through targeted therapeutic programs.
Investors
With our partners, Sensorion is committed to building and developing a cutting-edge therapeutic portfolio for major causes of hearing loss.
More informationSensorion focuses on innovative treatments that can restore, treat and prevent hearing loss.
Download our corporate presentation
NEWS & EVENTS
Sensorion announces that a General Meeting of shareholders will be held behind closed doors on May 18, 2021 alongside the publication of its 2020 annual financial report
Read the releaseSensorion senior management to attend four conferences in April 2021
Read the releaseSensorion publishes results of Extraordinary General Meeting resolutions
Read the releaseCareer
Entreprise Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) for sudden sensorineural hearing loss (SSNHL). Sensorion has built a unique R&D technology platform to expand its […]
Discover
04 67 20 77 30
